Logo

J&J Unit Veridex Licenses OncoMethylome's Prostate Cancer Dx

Dec 15, 2006
NEW YORK (GenomeWeb News) — OncoMethylome Sciences today said it has licensed a prostate cancer test it is developing to Johnson & Johnson subsidiary Veridex.
 
OncoMethylome said it has completed the initial research phase of the urine-based test, and said Veridex will finish developing it and will have the rights to market the resulting product worldwide.
 
The company said that under the agreement it will receive an undisclosed milestone payment now and will be due royalties and sales milestones in the future.  
 
OncoMethylome said a urine-based test is better than tissue-based tests because 75 percent of the biopsies that are performed based on prostate-specific antigens return negative results, and because those tests sometimes miss cancer when it is present.
 
Financial terms of the deal were not released.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.